cGMP Regulations and Quality Assurance in Pharmaceutical Industry

This report delves into the critical role of Current Good Manufacturing Practice (cGMP) regulations within the pharmaceutical industry, emphasizing their importance in ensuring drug quality, safety, and efficacy. It defines cGMP, highlighting its enforcement by the FDA and its function in regulating manufacturing processes to maintain quality control. The report outlines the key aspects of cGMP, including the control of raw materials, establishment of robust quality systems, and adherence to strict operating procedures. Furthermore, it examines the specific regulations for Piston Emission Tomography (PET) drugs, including personnel requirements, quality assurance functions, and the need for compliance with investigational new drug applications (INDs). The report underscores the flexibility within cGMP regulations that allows manufacturers to adopt innovative approaches while adhering to minimum requirements, ultimately contributing to continuous improvement in pharmaceutical manufacturing practices. The report concludes by emphasizing that the recommendations provided in cGMP documents are open to corrections and improvements within established guidelines.

INDUSTRIAL ENGINEERING
By Name
Course
Instructor
Institution
Location
Date

Introduction
The quality of drugs and food actually affect every individual in the whole world. This implies
that this quality of pharmaceutical products cuts across the entire group of personalities. The
regulation of the quality of pharmaceutical products normally follows specific requirements. The
main standard of regulation that ensures maintenance of the required quality is Current Good
Manufacturing Practice which is commonly abbreviated as cGMPs(Mosessian et al. 2014). It is
the expectation of each and every consumer that for every consumed drug, there is a guarantee of
effectiveness and safety. This invites very fundamental and strict regulations.
cGMPs definition, highlights, and its importance.
CGMPs simply refers to the regulations of current Good Manufacturing Practice that is under
enforcement by the FDA. cGMPs assist in the provision of a system that normally ensure that
there is regulated control, design and close monitoring of the processes of manufacturing.
Figure 1: Regulation fundamentals(Vighi et al. 2018)
Regulations

The strength, quality, purity, and identity of the drug products are normally observed by the strict
adherence to the regulations of cGMP. The requirement is therefore that manufacturers control
the operation and processes of manufacturing efficiency(Vighi et al. 2018). This includes
activities like obtaining the proper quality of raw materials, the establishment of strong and
effective quality systems of management, the creation of operating procedures that are very
robust, investigation and detection procedures of deviations from the product quality and finally
maintenance of testing laboratories that are reliable(Khalil 2017). The formal system of control
at the pharmaceutical company normally assists in the prevention of deviation, mix-uPs, errors,
contaminations, and failure. This is is only possible in the event that such ideas are put into
proper practice.
Figure 2: Pharmaceutical warehouse(Vighi et al. 2018)
In the regulation terms, establishment of the requirements of cGMP was done in a very flexible
way so as to allow each manufacturer to make an individual or independent decision. The
decision seeks to establish the best way of implementing the necessary control through the use of
effective techniques. Some of these processes utilizes methods, scientific design and other
mechanisms that are sound and effective in line with procedures of testing. The flexibilities in
the regulations have allowed the key players including manufacturers to apply the most

innovative approaches and modern technology to have higher quality achieved via continual
improvement. It is important to note that the listed requirements of cGMPs are just but a
minimum requirement(Hoover et al. 2016). Most of the companies dealing with pharmaceutical
products are already implementing modern quality systems.
The process of approval for new and generic drug marketing normally incorporates a review of
the compliance of the manufacturers with the cGMPs. The assessors and inspectors of the
facilities will determine whether the firm has the necessary equipment,facilities and the ability to
manufacture the drug that is intended to be introduced in the market(Schwarz, Dick,
VanBrocklin and Hoffman 2014).
Piston Emission Tomography Drugs
These are commonly known as PET drugs. The regulations of PET drugs handling are normally
found in the second part of 212 documents. According to this particular section, there is a
provision that all investigation regarding the use of the drug be done while considering human
safety. The production should, therefore, be done under investigational new drug application that
is also known as IND(Collier et al. 2017). This will be in accordance with part312 and the
requirement of PET drugs under the act which follows cGMPs. Approval must also be sought
from Radioactive Research Committee that is commonly known as RDRC.
Resources of Personnel
Requirements of regulation
According to section 212.10, the facility of PET drug production must possess enough number of
the persons who have relevant training, education, background, and experience. This will

actually enable them to perform their assigned functions correctly. There should be the provision
of adequate resources at every Centre. This will include facilities and equipment to be used by
personnel.
Staffing and Organization
It is usually recommended that the level of staffing correspond to the complexity and size of the
operations involving PET drug production. This will enable those facilities to have tasks
assigned to them completed within the required time. It is also recommended within the
regulation document that duties and responsibilities be assigned to the staff through clearly
written policies upon identification(Brooks et al. 2014).This is actually one of the surest way of
reaping importance or benefits of cGMPs.
Qualification of Personnel
As had been indicated previously, every individual who performs a function or an activity in the
quality assurance of PET drugs and production need to possess proper training, experience, and
education that is related to the expected duties. The training should be provided within the frame
of cGMPs. It is also recommended that PET drug production facilities be equipped with proper
progressive programs. Such programs seek to offer refresher courses to the employees and
address specific areas that may experience deficiencies.
Quality Assurance
According to 212.20, it is a requirement that the production of PET drug facilities possess very
high-quality assurance function. In the same regulation, there is a provision of the
responsibilities of quality assurance functions or team. Among these functions include

overseeing operations of productions so as to ensure that the drugs of PET have enough
definition of parameters which guides purity, identity, strength, and quality(Becker et al. 2017).
Figure 3: Quality Triology(Becker et al. 2017)
Conclusion
It is important to note that most of the contents that have been provided in the cGMPs documents
are just but recommendations. This implies that the system is open to corrections that will
contribute toward its perfection. The recommendations, however, must follow the proper
guidelines or framework that has been established.

References
Becker, G., Warner, C., Serrano, M.E., Bahri, M.A., Mercier, J., Lemaire, C., Salmon, E., Luxen,
A. and Plenevaux, A., 2017. Pharmacokinetic characterization of [18F] UCB-H PET
radiopharmaceutical in the rat brain. Molecular Pharmaceutics, 14(8), pp.2719-2725.
Brooks, A.F., Topczewski, J.J., Ichiishi, N., Sanford, M.S. and Scott, P.J., 2014. Late-stage [18
F] fluorination: new solutions to old problems. Chemical science, 5(12), pp.4545-4553.
Collier, T.L., Yokell, D.L., Livni, E., Rice, P.A., Celen, S., Serdons, K., Neelamegam, R.,
Bormans, G., Harris, D., Walji, A. and Hostetler, E.D., 2017. cGMP production of the
radiopharmaceutical [18F] MK‐6240 for PET imaging of human neurofibrillary tangles. Journal
of Labelled Compounds and Radiopharmaceuticals, 60(5), pp.263-269.
Hoover, A.J., Lazari, M., Ren, H., Narayanan, M.K., Murphy, J.M., van Dam, R.M., Hooker,
J.M. and Ritter, T., 2016. A transmetalation reaction enables the synthesis of [18F] 5-fluorouracil
from [18F] fluoride for human PET Imaging. Organometallics, 35(7), pp.1008-1014.
Khalil, M.M. ed., 2017. Basic science of PET imaging. Springer.
Mosessian, S., Duarte-Vogel, S.M., Stout, D.B., Roos, K.P., Lawson, G.W., Jordan, M.C.,
Ogden, A., Matter, C., Sadeghi, S., Mills, G.Q. and Schelbert, H.R., 2014. INDs for PET
Molecular Imaging Probes—Approach by an Academic Institution. Molecular Imaging and
Biology, 16(4), pp.441-448.
Schwarz, S.W., Dick, D., VanBrocklin, H.F. and Hoffman, J.M., 2014. Regulatory requirements
for PET drug production. Journal of Nuclear Medicine, 55(7), pp.1132-1137.

Vighi, E., Trifunović, D., Veiga-Crespo, P., Rentsch, A., Hoffmann, D., Sahaboglu, A., Strasser,
T., Kulkarni, M., Bertolotti, E., Van Den Heuvel, A. and Peters, T., 2018. Combination of cGMP
analog and drug delivery system provides functional protection in hereditary retinal
degeneration. Proceedings of the National Academy of Sciences, 115(13), pp.E2997-E3006.